urothelial carcinoma

Drug eluting stents can release locally pharmaceutical active ingredients, particularly in the ureter and bladder, increasing the bioavailability and efficacy of the drugs. Although drug eluting stents has been widely used and commercially available in other fields, such as cardiology, its role in urology is limited. In his work, we propose the production of biodegradable stents using a simple technology, developed and patented by the team as drug new drug delivery devices, namely for the delivery of anti-cancer drugs for the treatment of upper urinary tract urothelial carcinoma.

Using a well-established animal model of urothelial carcinoma, we performed urine proteome profiling from healthy animals and animals with urothelial carcinoma at two time-points of disease pathogenesis. Data analysis highlighted the biological processes involved in disease pathogenesis such as, for instance, response to selenium and to drugs, neutral lipid metabolism at earlier stages of disease, and inflammation, immune response and wound healing at advanced stages.

Authors and Affiliations: